The third study performed by Kang et al., 2021 did an in-depth analysis of FXS organoids and found deficits in cortical layer formation, synaptogenesis, electrical activity, and identified human-specific FMRP targets that can be pharmacologically manipulated to rescue these phenotypes [111]. The gene discussed is FMR1; the disease is fragile X syndrome.